While Intellia Therapeutics Inc has underperformed by -6.02%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, NTLA rose by 12.52%, with highs and lows ranging from $28.25 to $5.90, whereas the simple moving average jumped by 14.47% in the last 200 days.
On October 28, 2025, RBC Capital Mkts Downgraded Intellia Therapeutics Inc (NASDAQ: NTLA) to Sector Perform. A report published by Bernstein on October 28, 2025, Downgraded its rating to ‘Mkt Perform’ for NTLA. Citizens JMP October 06, 2025d its ‘Mkt Perform’ rating to ‘Mkt Outperform’ for NTLA, as published in its report on October 06, 2025. Wolfe Research’s report from April 21, 2025 suggests a price prediction of $21 for NTLA shares, giving the stock a ‘Outperform’ rating. H.C. Wainwright also rated the stock as ‘Buy’.
Analysis of Intellia Therapeutics Inc (NTLA)
Further, the quarter-over-quarter increase in sales is 104.76%, showing a positive trend in the upcoming months.
One of the most important indicators of Intellia Therapeutics Inc’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of -56.95% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 5.19, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and NTLA is recording 6.58M average volume. On a monthly basis, the volatility of the stock is set at 10.38%, whereas on a weekly basis, it is put at 11.32%, with a loss of -46.62% over the past seven days. Furthermore, long-term investors anticipate a median target price of $30.41, showing growth from the present price of $13.12, which can serve as yet another indication of whether NTLA is worth investing in or should be passed over.
How Do You Analyze Intellia Therapeutics Inc Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 5.39%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 90.21% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
